Last updated: 11/07/2018 00:44:34
An Open Phase II Study to Evaluate the Efficacy and Toxicity of Topotecan Administered Intravenously as Five Daily Infusions Every 21 Days to Patients with Advanced Non-Small Cell Lung Cancer.
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: An Open Phase II Study to Evaluate the Efficacy and Toxicity of Topotecan Administered Intravenously as Five Daily Infusions Every 21 Days to Patients with Advanced Non-Small Cell Lung Cancer.
Trial description: An Open Phase II Study to Evaluate the Efficacy and Toxicity of Topotecan Administered Intravenously as Five Daily Infusions Every 21 Days to Patients with Advanced Non-Small Cell Lung Cancer.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Perez-Soler R, Fossella FV, Glisson BS, et al. Phase II Study of Topotecan in Patients with Advanced Non-Small Cell Lung Cancer Previously Untreated with Chemotherapy. J Clin Oncol. 14 (2), 503-513, 1996.
Perez-Soler R, Glisson BS, Kane J, et al. Phase II Studies of Topotecan in Patients with Non-Small Cell Lung Cancer (NSCLC) Previously Untreated and Patients with Small Cell Lung Cancer (SCLC) Refractory to Etoposide. Presented at the 7th World Conference on Lung Cancer, Colorado Springs, CO, June 26-July 1, 1994.
Perez-Soler R, Khuri F, Pisters C, et al. Phase II Study of Topotecan in Patients with Squamous Carcinoma of the Lung Previously Untreated with Chemotherapy. ASCO Proceedings, 16, 450a, 1997.
Medical condition
Lung Cancer, Non-Small Cell
Product
topotecan
Collaborators
Not applicable
Study date(s)
March 1992 to October 1997
Type
Not applicable
Phase
2
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
1997-16-10
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website